SALT LAKE CITY and TORONTO, Jan. 23,
2015 /PRNewswire/ -- EastGate Biotech Corp. (OTCBB: ETBI),
an emerging pharmaceutical company exploring drug delivery
innovations for the development of novel formulations and
alternative dosage forms of existing biologically active molecules
receives an NPN (Natural Product Number) from the Natural and
Non-Prescription Health Products Directorate of Health Canada for
its natural product Glucora.
The NPN product license number for Glucora is 80057426.
Glucora is a natural based formula in self-emulsifying delivery
system that provides support for healthy glucose metabolism.
Glucora is an addition to a line of natural products, developed
at EastGate Biotech Corp. The products are currently
available online at www.nano-essentials.com. As previously
announced, the products will be also available under private label
by a distributor in the United
States.
EastGate Biotech's R&D strategy and product analysis
included the identification of biologically active compounds having
limited absorption due to low solubility. Low absorption of
drugs and poor bioavailability can lead to increased dosages taken
by patients with the same treatment result. Increased
bioavailability could encourage patient compliance, lower costs of
treatment, reduce side effects and improve quality of life.
EastGate Biotech's technology platform provides an effective
delivery system with increased bioavailability of incorporated
compounds. The Company's approach increases solubility of
hydrophobic compounds in a proprietary self-emulsifying vehicle
using a safe combination of known and approved excipients. To
date, the Company's sub-micron self-emulsifying delivery platform
has been used for improvement of dietary supplements as well as
pharmaceutical products. Intraoral Lorazepam Spray for
seizure treatment and in intraoral insulin tablet for diabetes are
in advanced stages of development.
"We are pleased with the addition of NPN license for our product
Glucora" says Anna Gluskin,
EastGate's CEO. "Both the nutraceutical and pharmaceutical
industries are consistently looking out for innovative products in
the area of glucose metabolism regulation that improve patient
compliance, since the consumer demand in diabetes management is
growing," continues Ms. Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact,
contained or incorporated by reference in this news release
constitute "forward-looking information" or "forward-looking
statements" within the meaning of certain securities laws,
including the provisions for "safe harbour" under the United States
Private Securities Litigation Reform Act of 1995 and are based on
expectations, estimates and projections as of the date of this news
release.
The words "anticipates", "plans", "expects", "indicate",
"intend", "scheduled", "estimates", "forecasts", "focus",
"guidance", "initiative", "model", "methodology", "outlook",
"potential", "projected", "pursue", "strategy", "study", "targets",
or "believes", or variations of or similar such words and phrases
or statements that certain actions, events or results "may",
"could", "would", or "should", "might", or "way forward", "will be
taken", "will occur" or "will be achieved" and similar expressions
identify forward-looking statements. Forward-looking statements are
necessarily based upon a number of estimates and assumptions that
are inherently subject to significant business, economic and
competitive risks, uncertainties and contingencies. The risks,
estimates, models and assumptions contained or incorporated by
reference in this release, include those identified from time to
time in the reports filed by EastGate with the SEC, which should be
considered together with any forward-looking statement.
EastGate undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/eastgate-biotech-corp-receives-an-npn-natural-product-number-for-its-product-glucora-designed-to-support-healthy-glucose-metabolism-300024641.html
SOURCE EastGate Biotech Corp.
